SERUM LEVELS OF INSULIN-LIKE GROWTH-FACTOR-I IN OPERABLE BREAST-CANCER IN RELATION TO THE MAIN PROGNOSTIC VARIABLES AND THEIR PERIOPERATIVECHANGES IN RELATION TO THOSE OF PROLACTIN
S. Barni et al., SERUM LEVELS OF INSULIN-LIKE GROWTH-FACTOR-I IN OPERABLE BREAST-CANCER IN RELATION TO THE MAIN PROGNOSTIC VARIABLES AND THEIR PERIOPERATIVECHANGES IN RELATION TO THOSE OF PROLACTIN, Tumori, 80(3), 1994, pp. 212-215
Aims and background: In addition to estrogens, prolactin (PRL) and IGF
-I have also appeared to stimulate breast cancer growth. The present s
tudy was performed to evaluate IGF-I blood levels in operable breast c
ancer in relation to PRL values and the main prognostic variables. Met
hods: The study included 40 patients, clinical stage T1-3NO-2MO. Venou
s blood samples were collected before and 7 days after surgery. PRL an
d IGF-I were measured by radioimmunoassay. The control group consisted
of 50 healthy women. Results: Mean serum levels of IGF-I were signifi
cantly higher in patients than in controls, without any apparent relat
ion to the main prognostic variables, including estrogen receptor and
node status. Surgery-induced hyperprolactinemia occurred in 22/40 pati
ents. IGF-I mean concentrations observed in the postoperative period i
n patients with surgery-induced hyperprolactinemia were significantly
lower than those seen in patients showing no postoperative PRL rise. C
onclusions: The study showed that operable breast cancer may be associ
ated with abnormally high levels of tumor growth factor IGF-I, and tha
t surgery was followed by an IGF-I decline only in patients who showed
surgery-induced hyperprolactinemia. Our previous studies have shown t
hat postoperative hyperprolactinemia is a favorable prognostic factors
for operable breast cancer. The present study, by showing that a post
operative PRL rise is associated with a fall in IGF-I, would suggest t
hat surgery-induced hyperprolactinemia may determine a lower tumor rel
apse rate by determining a diminished secretion of breast tumor growth
factor IGF-I.